Emtricitabine
- Generic Name
- Emtricitabine
- Brand Names
- Atripla, Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Truvada
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10FN3O3S
- CAS Number
- 143491-57-0
- Unique Ingredient Identifier
- G70B4ETF4S
- Background
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.
Emtricitabine was granted FDA approval on 2 July 2003.
- Indication
Emtricitabine is indicated in combination with other medications for the treatment of HIV-1 infections; treatment of HIV-1 infections in pediatric patients 25-35kg, treatment of HIV-1 infections in adult patients ≥35kg, for pre exposure prophylaxis of HIV-1 in adolescent and adult patients excluding those who have receptive vaginal sex; treatment of HIV-1 infections in pediatric and adult patients ≥17kg, pre exposure prophylaxis in adolescents and adults ≥35kg; treatment of HIV-1 in patients ≥12 years and ≥35kg; treatment of HIV-1 in patients weighing ≥35kg; treatment of HIV-1 in patients weighing ≥25kg; and treatment of HIV-1 in patients weighing ≥40kg.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Pre-Exposure Prophylaxis (PrEP)
Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 24
- Registration Number
- NCT00869960
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
- Conditions
- HIV-1
- Interventions
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 54
- Registration Number
- NCT00799864
Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT00743340
- Locations
- 🇿🇦
Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa
🇿🇦Themba Lethu Clinic, Helen Joseph Hospital, Westdene, Johannesburg, South Africa
An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 16
- Registration Number
- NCT00642291
Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults
- Conditions
- HIV Infections
- Interventions
- Drug: Lopinavir/ritonavirDrug: Emtricitabine/Tenofovir disoproxil fumarateDrug: Tenofovir disoproxil fumarateDrug: ZidovudineDrug: Emtricitabine
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 529
- Registration Number
- NCT00608569
- Locations
- 🇺🇬
JCRC CRS, Kampala, Uganda
🇭🇹Les Centres GHESKIO CRS, Bicentenaire, Port-au-Prince, Haiti
🇵🇪Barranco CRS, Lima, Peru
Characterization of Acute and Recent HIV-1 Infections in Zurich.
- Conditions
- HIV Infections
- Interventions
- Drug: DolutegravirDrug: Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid FumarateDrug: RaltegravirDrug: DarunavirDrug: RitonavirDrug: RilpivirineDrug: LamivudineDrug: tenofovirDrug: EmtricitabineDrug: Abacavir
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 800
- Registration Number
- NCT00537966
- Locations
- 🇨🇭
University of Zurich, Zurich, Switzerland
Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infection
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2016-02-22
- Target Recruit Count
- 24
- Registration Number
- NCT00476463
- Locations
- 🇹🇭
HIV-NAT Thai Red Cross AIDS Research Center, Bangkok, Thailand
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
- Conditions
- Human Immunodeficiency Virus (HIV)-1 Infection
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT00380159
- Locations
- 🇪🇸
Clinical Trial Site, Madrid, Spain
Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection
- Conditions
- HIV InfectionsHepatitis B
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2007-04-24
- Lead Sponsor
- International Antiviral Therapy Evaluation Center
- Target Recruit Count
- 24
- Registration Number
- NCT00127959
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, NH, Netherlands
Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)
- Conditions
- HIV InfectionsTuberculosis
- First Posted Date
- 2005-06-24
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Target Recruit Count
- 70
- Registration Number
- NCT00115609
- Locations
- 🇫🇷
Service des maladies Infectieuses et tropicales Hopital Necker-Enfants Malades, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.